New Medical Technologies

New Medical Technologies (NMT) is a Swiss-based specialty pharmaceutical company dedicated to developing innovative treatments for the supportive care of cancer patients. The company focuses on addressing the debilitating side effects of oncology therapies, such as oral mucositis, radiation dermatitis, and hand-foot syndrome, which can significantly impact patient quality of life and treatment adherence. NMT's lead product candidate, NMT-107, is a proprietary topical formulation of clobetasol propionate that has reached Phase 3 clinical trials for the prevention and treatment of oral mucositis. By utilizing advanced formulation technologies to optimize the delivery of established therapeutic agents, NMT aims to provide effective, localized solutions for unmet needs in oncology supportive care. The company operates with a strategic focus on global markets and has established partnerships with major regional pharmaceutical players and investment groups.